T 1032

a cyclic GMP phosphodiesterase-5 inhibitor; structure in first source

Also Known As:

3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1); T-1032; methyl 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinolinecarboxylate

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - T 1032: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - T 1032: 4

Experts

1.	Ikeo, Tomihiro: 2 articles (11/2002 - 05/2002)
2.	Inoue, Hirotaka: 2 articles (11/2002 - 05/2002)
3.	Kikkawa, Kohei: 2 articles (11/2002 - 05/2002)
4.	Noto, Tsunehisa: 2 articles (11/2002 - 05/2002)
5.	Takagi, Michino: 2 articles (11/2002 - 05/2002)
6.	Yano, Koji: 2 articles (11/2002 - 05/2002)
7.	Aigrain, Yves: 1 article (08/2011)
8.	Dinh-Xuan, Anh Tuan: 1 article (08/2011)
9.	Fouquet, Virginie: 1 article (08/2011)
10.	Mercier, Jean-Christophe: 1 article (08/2011)

Related Diseases

1.	Vascular Ring 08/01/2011 - "In vitro, the stimulation of GC by 3(5'hydroxymethyl-2'furyl)-1-benzyl indazole (YC-1) (a benzyl indazole derivative) and the inhibition of PDE 5 by T-1032 were less effective in pulmonary vascular rings from CDH animals. "
2.	Ventricular Remodeling 11/01/2002 - "Our present results suggest that T-1032 selectively reduces RVSP, and resulting in the suppression of right ventricular remodeling with a delay of the death in MCT-induced pulmonary hypertensive rats." 11/01/2002 - "When T-1032 (300 ppm in diet) was chronically administered, it delayed the death, and significantly suppressed right ventricular remodeling (T-1032-treated: 0.318+/-0.021 g, control: 0.401+/-0.013 g, p<0.05). "
3.	Erectile Dysfunction 09/01/2000 - "These data suggest that oral treatment with T-1032 has potential to improve erectile dysfunction through the inhibition of phosphodiesterase type V in the smooth muscles of corpus cavernosa."
4.	Pulmonary Hypertension 11/01/2002 - "Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats."
5.	Heart Failure 05/17/2002 - "It was concluded that T-1032 had beneficial hemodynamic effects on heart failure in Bio 14.6 cardiomyopathic hamsters, and the favorable hemodynamic changes induced by T-1032 were partly related to the increase in the survival of these hamsters. " 05/17/2002 - "To evaluate the influence of T-1032 (methyl2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate), a potent and relatively selective phosphodiesterase 5 inhibitor, on chronic heart failure, we examined the acute hemodynamic profile of T-1032 and its chronic effect on the survival of Bio 14.6 cardiomyopathic hamsters. "

Related Drugs and Biologics

1.	Indazoles
2.	Phosphodiesterase 5 Inhibitors
3.	T 1032
4.	Type 5 Cyclic Nucleotide Phosphodiesterases
5.	Monocrotaline